NEW YORK (GenomeWeb) – LGC said today that it has acquired Lucigen, a developer, manufacturer, and supplier of molecular biology enzymes, reagents, and kits, for an undisclosed amount.
Founded in 1998, Lucigen currently employs over 65 people at its Middleton, Wisconsin site. It has an extensive portfolio of life science products including next-generation sequencing kits, enzymes, competent cells, and cloning systems, targeting fast growth applications in clinical diagnostics, drug discovery, synthetic biology, and gene editing.
LGC said that the acquisition increases its exposure to the NGS and gene editing markets.
"Lucigen has tremendous assets including its highly skilled and motivated workforce, enzyme, and kit development capabilities, complemented by ISO 13485 manufacturing," Brian Kim, president and managing director of LGC's genomics division, said in a statement. "Lucigen's assets are highly complementary to LGC's capabilities, aligning squarely with our strategy to expand in the NGS and gene editing markets. We are excited to join forces and improve our offering to our molecular diagnostic, agbio, and biopharma customers."
LGC, based in London, provides products and services to the life sciences sector, including for human healthcare, agri-food, and environmental sciences. The company provides a comprehensive range of reference materials, proficiency testing schemes, genomics reagents and instrumentation, and research and measurement services.